{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T20:10:52Z","timestamp":1767903052064,"version":"3.49.0"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2013,6,19]],"date-time":"2013-06-19T00:00:00Z","timestamp":1371600000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1007\/s00280-013-2213-y","type":"journal-article","created":{"date-parts":[[2013,6,18]],"date-time":"2013-06-18T01:43:16Z","timestamp":1371519796000},"page":"489-490","source":"Crossref","is-referenced-by-count":16,"title":["Ipilimumab-induced endocrinopathies: when to start corticosteroids (or not)"],"prefix":"10.1007","volume":"72","author":[{"given":"Salvatore Maria","family":"Corsello","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Salvatori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnese","family":"Barnabei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liana","family":"De Vecchis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Marchetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Torino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,6,19]]},"reference":[{"key":"2213_CR1","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1210\/jc.2012-4075","volume":"98","author":"SM Corsello","year":"2013","unstructured":"Corsello SM, Barnabei A, Marchetti P, De Vecchis L, Salvatori R, Torino F (2013) Endocrine side effects induced by immune checkpoint inhibitors. J Clin Endocrinol Metab 98:1361\u20131375","journal-title":"J Clin Endocrinol Metab"},{"key":"2213_CR2","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1634\/theoncologist.2011-0404","volume":"17","author":"F Torino","year":"2012","unstructured":"Torino F, Barnabei A, De Vecchis L, Salvatori R, Corsello SM (2012) Hypophysitis induced by monoclonal antibodies to cytotoxic T lymphocyte antigen 4: challenges from a new cause of a rare disease. Oncologist 17:525\u2013535","journal-title":"Oncologist"},{"key":"2213_CR3","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1200\/JCO.2012.41.6750","volume":"30","author":"JS Weber","year":"2012","unstructured":"Weber JS, K\u00e4hler KC, Hauschild A (2012) Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 30:2691\u20132697","journal-title":"J Clin Oncol"},{"key":"2213_CR4","unstructured":"Yervoy (ipilimumab): serious and fatal immune-mediated adverse reactions. www.yervoy.com\/hcp\/rems"},{"key":"2213_CR5","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1097\/01.cji.0000178913.41256.06","volume":"28","author":"JA Blansfield","year":"2005","unstructured":"Blansfield JA, Beck KE, Tran K, Yang JC, Hughes MS, Kammula US, Royal RE, Topalian SL, Haworth LR, Levy C, Rosenberg SA, Sherry RM (2005) Cytotoxic T-lymphocyte associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J Immunother 28:593\u2013598","journal-title":"J Immunother"},{"key":"2213_CR6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1530\/EJE-12-0167","volume":"167","author":"A Juszczak","year":"2012","unstructured":"Juszczak A, Gupta A, Karavitaki N, Middleton MR, Grossman AB (2012) Ipilimumab: a novel immunomodulating therapy causing autoimmune hypophysitis: a case report and review. Eur J Endocrinol 167:1\u20135","journal-title":"Eur J Endocrinol"},{"key":"2213_CR7","doi-asserted-by":"crossref","first-page":"351","DOI":"10.4158\/EP11273.OR","volume":"18","author":"L Min","year":"2012","unstructured":"Min L, Vaidya A, Becker C (2012) Association of ipilimumab therapy for advanced melanoma with secondary adrenal insufficiency: a case series. Endocr Pract 18:351\u2013355","journal-title":"Endocr Pract"},{"key":"2213_CR8","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.3174\/ajnr.A1623","volume":"30","author":"KJ Carpenter","year":"2009","unstructured":"Carpenter KJ, Murtagh RD, Lilienfeld H, Weber J, Murtagh FR (2009) Ipilimumab-induced hypophysitis: MR imaging findings. AJNR Am J Neuroradiol 30:1751\u20131753","journal-title":"AJNR Am J Neuroradiol"},{"key":"2213_CR9","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1093\/jnci\/djr373","volume":"103","author":"OP Hamnvik","year":"2011","unstructured":"Hamnvik OP, Larsen PR, Marqusee E (2011) Thyroid dysfunction from antineoplastic agents. J Natl Cancer Inst 103:1572\u20131587","journal-title":"J Natl Cancer Inst"},{"key":"2213_CR10","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1530\/EJE-10-0833","volume":"164","author":"L Min","year":"2011","unstructured":"Min L, Vaidya A, Becker C (2011) Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy. Eur J Endocrinol 164:303\u2013307","journal-title":"Eur J Endocrinol"},{"key":"2213_CR11","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1097\/IOP.0b013e3181ef72a1","volume":"27","author":"G Borodic","year":"2011","unstructured":"Borodic G, Hinkle DM, Cia Y (2011) Drug-induced Graves\u2019 disease from CTLA-4 receptor suppression. Ophthal Plast Reconstr Surg 27:e87\u2013e88","journal-title":"Ophthal Plast Reconstr Surg"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-013-2213-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-013-2213-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-013-2213-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T06:11:30Z","timestamp":1559023890000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-013-2213-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6,19]]},"references-count":11,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["2213"],"URL":"https:\/\/doi.org\/10.1007\/s00280-013-2213-y","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,6,19]]}}}